With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.787618-22-8,Dicyclohexyl(2′,6′-diisopropoxy-[1,1′-biphenyl]-2-yl)phosphine,as a common compound, the synthetic route is as follows.
787618-22-8, REFERENCE EXAMPLE 584 Preparation of (2S)-1-[4-({[t-butyl(dimethyl)silyl]oxy}methyl)phenyl]-2-(trifluoromethyl)pyrrolidine A suspension of [(4-bromobenzyl)oxy](t-butyl)dimethylsilane (1.0 g), (2S)-2-(trifluoromethyl)pyrrolidine (695 mg), tris(dibenzylideneacetone)palladium(0) (302 mg), 2-dicyclohexyl-phosphino-2′,6′-diisopropoxybiphenyl (308 mg) and sodium t-butoxide (638 mg) in 1,2-dimethoxyethane (50 mL) was stirred for 2 hours at 90 C. under nitrogen atmosphere. NH-silica gel and ethyl acetate were added to the reaction mixture, and the insoluble materials were removed by filtration. The filtrate was concentrated under reduced pressure, and the resulting residue was purified by NH-silica gel column chromatography (solvent: hexane/ethyl acetate=100/0 to 50/50), followed by silica gel column chromatography (solvent: hexane/ethyl acetate=90/10 to 20/80) to yield the titled compound (1.12 g, 94% yield). 1H NMR (400 MHz, CHLOROFORM-d) delta ppm 7.21 (d, J=8.70 Hz, 2H), 6.74 (d, J=8.70 Hz, 2H), 4.65 (s, 2H), 4.21 (m, 1H), 3.60-3.69 (m, 1H), 3.16-3.26 (m, 1H), 2.12-2.29 (m, 2H), 1.95-2.11 (m, 2H), 0.93 (s, 9H), 0.08 (s, 6H).
As the paragraph descriping shows that 787618-22-8 is playing an increasingly important role.
Reference£º
Patent; MITSUBISHI TANABE PHARMA CORPORATION; Nakajima, Tatsuo; Goi, Takashi; Kawata, Atsushi; Sugahara, Masakatsu; Yamakoshi, Shuhei; US2015/239889; (2015); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate